Dr. Finn on New CDK 4/6 Inhibitors for Breast Cancer

Richard S. Finn, MD
Published Online: Monday, Aug 19, 2013
Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Other CDK inhibitors have been around a lot longer than palbociclib but have not broken out of the pack to show robust activity. Palbociclib, as a first-in-class CDK 4/6 inhibitor, has shown such benefit that there are now other CDK 4/6 inhibitors being developed.

These other drugs are in early phase and a ways behind, Finn says, so it remains to be seen how they can compete with palbociclib in the space.

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Other CDK inhibitors have been around a lot longer than palbociclib but have not broken out of the pack to show robust activity. Palbociclib, as a first-in-class CDK 4/6 inhibitor, has shown such benefit that there are now other CDK 4/6 inhibitors being developed.

These other drugs are in early phase and a ways behind, Finn says, so it remains to be seen how they can compete with palbociclib in the space.

Online CME Activities
TitleExpiration DateCME Credits
32nd Annual Miami Breast Cancer Conference® Community Practice ConnectionsMay 29, 20161.25
PARP Inhibitors: Current and Future Options for Breast and Ovarian CancerJun 20, 20161.0